<code id='F3CCB3D368'></code><style id='F3CCB3D368'></style>
    • <acronym id='F3CCB3D368'></acronym>
      <center id='F3CCB3D368'><center id='F3CCB3D368'><tfoot id='F3CCB3D368'></tfoot></center><abbr id='F3CCB3D368'><dir id='F3CCB3D368'><tfoot id='F3CCB3D368'></tfoot><noframes id='F3CCB3D368'>

    • <optgroup id='F3CCB3D368'><strike id='F3CCB3D368'><sup id='F3CCB3D368'></sup></strike><code id='F3CCB3D368'></code></optgroup>
        1. <b id='F3CCB3D368'><label id='F3CCB3D368'><select id='F3CCB3D368'><dt id='F3CCB3D368'><span id='F3CCB3D368'></span></dt></select></label></b><u id='F3CCB3D368'></u>
          <i id='F3CCB3D368'><strike id='F3CCB3D368'><tt id='F3CCB3D368'><pre id='F3CCB3D368'></pre></tt></strike></i>

          entertainment

          entertainment

          author:fashion    Page View:1684
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Senate panel puts off hardest PBM reforms for another day
          Senate panel puts off hardest PBM reforms for another day

          SenateFinanceCommitteeChairRonWyden(D-Ore.)LeahMillis/PoolviaAPWASHINGTON—SenatorsontheFinanceCommit

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          UHS says company favors patients whose insurance pays more

          Thefinancechiefofthecountry’slargestprivatepsychiatrichospitaloperator,UHS,madeabluntstatementtoday: